-
Company Insights
NewM-PESA – Competitor Profile
M-PESA is a mobile-based fund transfer and micro-level banking service available to customers of Safaricom, Kenya’s largest mobile network. Introduced in 2007, the service has become a primary channel for fund transfers in the country. Originally developed as a low-cost microfinance loan repayment system, it was extended as an open platform to remit funds and make consumer payments due to its rising popularity. This was largely a result of factors such as the high cost of remitting funds through banks,...
-
Product Insights
Serine Protein Kinase ATM – Drugs In Development, 2023
Global Markets Direct’s Serine Protein Kinase ATM provides in depth analysis on Serine Protein Kinase ATM targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine Protein Kinase...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – M-4076 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - M-4076 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-4076 in Solid Tumor Drug Details: M-4076 is under development for the...
-
Company Insights
Royal Bank of Canada – Digital Transformation Strategies
RBC Digital Transformation Strategies Report Overview Royal Bank of Canada (RBC) has been focusing on using artificial intelligence, machine learning, cloud, big data, and blockchain to digitally transform its operations. The annual ICT spending of RBC was estimated at $725.1 million for 2023. A major share of this spending is earmarked for acquiring software, consulting, and hardware from vendors. RBC is a multinational financial institution providing personal and business banking, wealth management, and institutional banking services. The personal and business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Leiomyosarcoma Drug Details: AZD-1390 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is...